BOSTON , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase
BOSTON , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm.
– Encouraging long-term outcome data after infusion of Sleeping Beauty -modified CAR-T published in Blood – – TCRs targeting mutations in TP53 obtained from T cells in peripheral blood to overcome need for surgical resection published in Clinical Cancer Research – BOSTON , Jan.
BOSTON , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,
BOSTON , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019 .
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON , Dec. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq:ZIOP), today
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorable safety profile and initial data
Presentation moved to 1:20 p.m. GMT (8:20 a.m. ET) on November 20, 2019 BOSTON , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , has been moved to 1:20
BOSTON , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , beginning
– Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD Anderson Cancer Center to expand library of T-cell receptors (TCRs) targeting neoantigens; Enables new clinical trials – – Balance sheet
